Association between type-three metabotropic glutamate receptor gene (GRM3) variants and symptom presentation in treatment refractory schizophrenia

Human Psychopharmacology

Volumn 26, Issue 1, 2011, Pages 28-34

  Bishop, Jeffrey R ^a   Miller, Del D ^b   Ellingrod, Vicki L ^c,d   Holman, Timothy ^b  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b UNIVERSITY OF IOWA   (United States)

^c UNIVERSITY OF MICHIGAN   (United States)

^d UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

Antipsychotic; Glutamate; Metabotropic; Pharmacogenetics; Schizophrenia

Indexed keywords

CLOZAPINE; METABOTROPIC RECEPTOR 3; NEUROLEPTIC AGENT;

ADULT; ALLELE; ARTICLE; BRIEF PSYCHIATRIC RATING SCALE; CONTROLLED STUDY; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC RESISTANCE; GENETIC RISK; GENOTYPE; GLOBAL PSYCHOSIS SYMPTOM; HAPLOTYPE; HETEROZYGOTE; HUMAN; MAJOR CLINICAL STUDY; MALE; NEGATIVE SYNDROME; PRIORITY JOURNAL; PSYCHOLOGICAL RATING SCALE; PSYCHOPHARMACOTHERAPY; PSYCHOSIS; SCALE FOR ASSESSMENT OF NEGATIVE SYMPTOMS; SCHIZOPHRENIA; SINGLE NUCLEOTIDE POLYMORPHISM;

ADULT; ANTIPSYCHOTIC AGENTS; FEMALE; GENOTYPE; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; PSYCHIATRIC STATUS RATING SCALES; RECEPTORS, METABOTROPIC GLUTAMATE; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY;

EID: 79953241037     PISSN: 08856222     EISSN: 10991077     Source Type: Journal    
DOI: 10.1002/hup.1163     Document Type: Article

References (35)

1. Albalushi T, Horiuchi Y, Ishiguro H, et al. 2008. Replication study and meta-analysis of the genetic association of GRM3 gene polymorphisms with schizophrenia in a large Japanese case-control population. Am J Med Genet B Neuropsychiatr Genet 147: 392-396. (Pubitemid 351536806)
2. Barrett JC, Fry B, Maller J, Daly MJ. 2005. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 21: 263-265. (Pubitemid 40202029)
3. Bishop JR, Ellingrod VL, Moline J, Miller D. 2005. Association between the polymorphic GRM3 gene and negative symptom improvement during olanzapine treatment. Schizophr Res 77: 253-260. (Pubitemid 41112218)
4. Bishop JR, Wang K, Moline J, Ellingrod VL. 2007. Association analysis of the metabotropic glutamate receptor type 3 gene (GRM3) with schizophrenia. Psychiatr Genet 17: 358. (Pubitemid 351339822)
5. Cartmell J, Schoepp DD. 2000. Regulation of neurotransmitter release by metabotropic glutamate receptors. J Neurochem 75: 889-907. (Pubitemid 30660476)
6. Chen Q, He G, Chen Q, et al. 2005. A case-control study of the relationship between the metabotropic glutamate receptor 3 gene and schizophrenia in the Chinese population. Schizophr Res 73: 21-26. (Pubitemid 39574674)
7. Conn PJ, Pin JP. 1997. Pharmacology and functions of metabotropic glutamate receptors. Ann Rev Pharmacol Toxicol 37: 205-237. (Pubitemid 27238875)
8. Corti C, Xuereb JH, Corsi M, Ferraguti F. 2001. Identification and characterization of the promoter region of the GRM3 gene. Biochem Biophys Res Commun 286: 381-387. (Pubitemid 32924925)
9. Egan MF, Straub RE, Goldberg TE, et al. 2004. Variation in GRM3 affects cognition, prefrontal glutamate, and risk for schizophrenia. Proc Natl Acad Sci USA 101: 12604-12609. (Pubitemid 39122071)
10. Fallin MD, Lasseter VK, Avramopoulos D, et al. 2005. Bipolar I disorder and schizophrenia: a 440-single-nucleotide polymorphism screen of 64 candidate genes among Ashkenazi Jewish case-parent trios. Am J Hum Genet 77: 918-936. (Pubitemid 41698514)
11. Fijal BA, Kinon BJ, Kapur S, et al. 2009. Candidate-gene association analysis of response to risperidone in African-American and white patients with schizophrenia. Pharmacogenomics J 9: 311-318.
12. Fujii Y, Shibata H, Kikuta R, et al. 2003. Positive associations of polymorphisms in the metabotropic glutamate receptor type 3 gene (GRM3) with schizophrenia. Psychiatr Genet 13: 71-76. (Pubitemid 36724534)
13. Girgenti MJ, Nisenbaum LK, Bymaster F, Terwilliger R, Duman RS, Newton SS. 2010. Antipsychotic-induced gene regulation in multiple brain regions. J Neurochem 113: 175-187.
14. Goff DC, Hennen J, Lyoo IK, et al. 2002. Modulation of brain and serum glutamatergic concentrations following a switch from conventional neuroleptics to olanzapine. Biol Psychiatry 51: 493-497. (Pubitemid 34260971)
15. Harrison PJ, Lyon L, Sartorius LJ, Burnet PW, Lane TA. 2008. The group II metabotropic glutamate receptor 3 (mGluR3, mGlu3, GRM3): expression, function and involvement in schizophrenia. J Psychopharmacol 22: 308-322. (Pubitemid 351847454)
16. Javitt DC. 2006. Is the glycine site half saturated or half unsaturated? Effects of glutamatergic drugs in schizophrenia patients. Curr Opin Psychiatry 19: 151-157. (Pubitemid 44406126)
17. Jonsson EG, Saetre P, Vares M, et al. 2009. DTNBP1, NRG1, DAOA, DAO and GRM3 polymorphisms and schizophrenia: an Association Study. Neuropsychobiology 59: 142-150.
18. Kane JM, Honigfeld G, Singer J, Meltzer H. 1988. Clozapine in treatment-resistant schizophrenics. Psychopharmacol Bull 24: 62-67.
19. Lahiri DK, Nurnberger JI, Jr. 1991. A rapid non-enzymatic method for the preparation of HMW DNA from blood for RFLP studies. Nucleic Acids Res 19: 5444.
20. Marti SB, Cichon S, Propping P, Nothen M. 2002. Metabotropic glutamate receptor 3 (GRM3) gene variation is not associated with schizophrenia or bipolar affective disorder in the German population. Am J Med Genet 114: 46-50.
21. Moghaddam B. 2004. Targeting metabotropic glutamate receptors for treatment of the cognitive symptoms of schizophrenia. Psychopharmacology (Berl) 174: 39-44. (Pubitemid 38925089)
22. Molteni R, Calabrese F, Racagni G, Fumagalli F, Riva MA. 2009. Antipsychotic drug actions on gene modulation and signaling mechanisms. Pharmacol Ther 124: 74-85.
23. Nakanishi S. 1992. Molecular diversity of glutamate receptors and implications for brain function. Science 258: 597-603.
24. Nicodemus KK, Kolachana BS, Vakkalanka R, et al. 2007. Evidence for statistical epistasis between catechol-O-methyltransferase (COMT) and polymorphisms in RGS4, G72 (DAOA), GRM3, and DISC1: influence on risk of schizophrenia. Hum Genet 120: 889-906. (Pubitemid 46128844)
25. Norton N, Williams HJ, Dwyer S, et al. 2005. No evidence for association between polymorphisms in GRM3 and schizophrenia. BMC Psychiatry 5: 23.
26. Patil ST, Zhang L, Martenyi F, et al. 2007. Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial. Nat Med 13: 1102-1107. (Pubitemid 47517511)
27. Purcell S, Neale B, Todd-Brown K, et al. 2007. PLINK: a tool set for whole-genome association and population-based linkage analyses. Am J Hum Genet 81: 559-575. (Pubitemid 47330214)
28. Riva MA, Tascedda F, Lovati E, Racagni G. 1997. Regulation of NMDA receptor subunit messenger RNA levels in the rat brain following acute and chronic exposure to antipsychotic drugs. Brain Res Mol Brain Res 50: 136-142. (Pubitemid 27488900)
29. Scherer SW, Duvoisin RM, Kuhn R, Heng HH, Belloni E, Tsui LC. 1996. Localization of two metabotropic glutamate receptor genes, GRM3 and GRM8, to human chromosome 7q. Genomics 31: 230-233. (Pubitemid 26044779)
30. Schwab SG, Plummer C, Albus M, et al. 2008. DNA sequence variants in the metabotropic glutamate receptor 3 and risk to schizophrenia: an association study. Psychiatr Genet 18: 25-30.
31. Tamminga CA. 2006. The neurobiology of cognition in schizophrenia. J Clin Psychiatry 67 (Suppl 9): 9-13; discussion 36-42.
32. Tan HY, Chen Q, Sust S, et al. 2007. Epistasis between catechol-O-methyltransferase and type II metabotropic glutamate receptor 3 genes on working memory brain function. Proc Natl Acad Sci USA 104: 12536-12541. (Pubitemid 47206173)
33. Tascedda F, Blom JM, Brunello N, et al. 2001. Modulation of glutamate receptors in response to the novel antipsychotic olanzapine in rats. Biol Psychiatry 50: 117-122. (Pubitemid 32728211)
34. Tochigi M, Suga M, Ohashi J, et al. 2006. No association between the metabotropic glutamate receptor type 3 gene (GRM3) and schizophrenia in a Japanese population. Schizophr Res 88: 260-264. (Pubitemid 44693245)
35. Woods SW. 2003. Chlorpromazine equivalent doses for the newer atypical antipsychotics. J Clin Psychiatry 64: 663-667. (Pubitemid 36750143)